Sagimet Biosciences

SGMTPhase 3

Sagimet Biosciences is pioneering a novel therapeutic approach by selectively inhibiting the fatty acid synthase (FASN) enzyme, a key regulator of lipid synthesis implicated in multiple diseases. The company's lead asset, denifanstat, has demonstrated statistically significant efficacy in a Phase 2b MASH trial and met all endpoints in a Phase 3 acne trial, supported by FDA Breakthrough Therapy designation for MASH. With a pipeline extending to oncology and a second FASN inhibitor, TVB-3567, entering clinical development for acne, Sagimet is positioned to address significant unmet needs in metabolic, dermatological, and oncological diseases.

Market Cap

$157.1M

Focus

Small Molecules

AI Company Overview

Technology Platform

Development of selective, oral small-molecule inhibitors of Fatty Acid Synthase (FASN), the key enzyme in the de novo lipogenesis pathway, to treat diseases driven by overproduction of the fatty acid palmitate.

Pipeline Snapshot

12 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
denifanstat + Placebo	MASLD	Phase 3
Denifanstat + Placebo	MASH	Phase 3
TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China...	MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)	Phase 2
TVB-2640	KRAS Gene Mutation	Phase 2
TVB-2640	Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease	Phase 2

Funding History

Total raised: $165M

IPO$75MUndisclosedJul 28, 2023

Series C$40MUndisclosedJun 15, 2018

Series B$30MUndisclosedJun 15, 2014

Series A$20MUndisclosedJun 15, 2010

Opportunities

Sagimet's core FASN inhibition platform offers a unique opportunity to address multiple large markets (MASH, acne, oncology) with a single mechanistic approach.

The positive late-stage data in two distinct indications de-risks the platform and creates multiple value inflection points.

Strategic partnerships for ex-U.S.

rights or specific indications could provide non-dilutive funding.

Risk Factors

The company faces significant clinical risk in upcoming Phase 3 trials for MASH, regulatory uncertainty, and intense competition in its core markets.

As a pre-revenue company, it remains highly dependent on the capital markets to fund operations, creating dilution risk for shareholders.

Competitive Landscape

In MASH, Sagimet competes with Madrigal, 89bio, Akero, and Viking, differentiating via its direct FASN inhibition mechanism. In acne, it offers a potential new oral systemic alternative to isotretinoin. In oncology, it is a early mover in targeting FASN, a pathway linked to tumor aggressiveness and treatment resistance.